DOSSIER · 13F Holders · Q1 2026Healthcare · Biological Products, (No Diagnostic Substances)
RXRX
RECURSION PHARMACEUTICALS IN
366 institutions still hold RECURSION PHARMACEUTICALS IN as of Q1 2026. Tracked across SEC 13F-HR filings, with insider and 13D/G activity surfaced alongside.
CUSIP 75629V104·Biological Products, (No Diagnostic Substances)·366 13F holders·last filed Mar 31, 2026
AI Holders Summary · Q1 2026
366 institutions reported RXRX in Q1 2026. BlackRock, Inc. leads at 14.3% of the visible book.
Top holders
Sorted by position value. Source: SEC EDGAR 13F-HR filings.
Page 1 of 19
346 more holders available. Log in →